Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects

Kidney International

Volumn 69, Issue 9, 2006, Pages 1535-1542

  Yasuda, H ^a   Yuen, P S T ^a   Hu, X ^a   Zhou, H ^a   Star, R A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Extravasation; Hypoxia; Inflammation; Microvascular permeability; TNF

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUTRALIZING ANTIBODY; SIMVASTATIN; STATINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; HYPOXIA; KIDNEY BLOOD VESSEL; KIDNEY INJURY; KIDNEY PERFUSION; KIDNEY TUBULE DAMAGE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL; SYSTEMIC THERAPY;

ANIMALS; ANOXIA; ANTIBODIES; BLOOD VESSELS; DELAYED-ACTION PREPARATIONS; KIDNEY FAILURE, ACUTE; KIDNEY TUBULES; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICROCIRCULATION; PERMEABILITY; RENAL CIRCULATION; SEPSIS; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646519915     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000300     Document Type: Article

References (67)

1. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365: 417-430.
2. Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818.
3. Rangel-Frausto MS, Pittet D, Costigan M et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117-123.
4. Neveu H, Kleinknecht D, Brivet F et al. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 1996; 11: 293-299.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494.
6. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
7. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
8. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
9. De Vriese AS. Prevention and treatment of acute renal failure in sepsis. J Am Soc Nephrol 2003; 14: 792-805.
10. Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002; 137: 744-752.
11. Wang P, Yoo P, Zhou M et al. Reduction in vascular responsiveness to adrenomedullin during sepsis. J Surg Res 1999; 85: 59-65.
12. Wang P, Zhou M, Rana MW et al. Differential alterations in microvascular perfusion in various organs during early and late sepsis. Am J Physiol 1992; 263: G38-G43.
13. Yang S, Chung CS, Ayala A et al. Differential alterations in cardiovascular responses during the progression of polymicrobial sepsis in the mouse. Shock 2002; 17: 55-60.
14. Dear JW, Kobayashi H, Jo SK et al. Dendrimer-enhanced MRI as a diagnostic and prognostic biomarker of sepsis-induced acute renal failure in aged mice. Kidney Int 2005; 67: 2159-2167.
15. Miyaji T, Hu X, Yuen PS et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 2003; 64: 1620-1631.
16. Mason JC. The statins - therapeutic diversity in renal disease? Curr Opin Nephrol Hypertens 2005; 14: 17-24.
17. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2-14.
18. Khanal S, Attallah N, Smith DE et al. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-849.
19. Pierre-Paul D, Gahtan V. Noncholesterol-lowering effects of statins. Vasc Endovascular Surg 2003; 37: 301-313.
20. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
21. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
22. Liappis AP, Kan VL, Rochester CG et al. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352-1357.
23. Almog Y, Shefer A, Novack V et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-885.
24. Merx MW, Liehn EA, Janssens U et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109: 2560-2565.
25. Merx MW, Liehn EA, Graf J et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005; 112: 117-124.
26. Wang le F, Patel M, Razavi HM et al. Role of inducible nitric oxide synthase in pulmonary microvascular protein leak in murine sepsis. Am J Respir Crit Care Med 2002; 165: 1634-1639.
27. Whittle BJ, Morschl E, Pozsar J et al. Helicobacter pylori lipopolysaccharide provokes iNOS-mediated acute systemic microvascular inflammatory responses in rat cardiac, hepatic, renal and pulmonary tissues. J Physiol Paris 2001; 95: 257-259.
28. Carrithers M, Tandon S, Canosa S et al. Enhanced susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice. Am J Pathol 2005; 166: 185-196.
29. Peng X, Hassoun PM, Sammani S et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004; 169: 1245-1251.
30. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-891.
31. Franko AJ, Chapman JD. Binding of 14C-misonidazole to hypoxic cells in V79 spheroids. Br J Cancer 1982; 45: 694-699.
32. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-295.
33. Schrier RW. Cancer therapy and renal injury. J Clin Invest 2002; 110: 743-745.
34. Bonetti PO, Lerman LO, Napoli C et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003; 24: 225-248.
35. Yokota N, O'Donnell M, Daniels F et al. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol 2003; 23: 13-17.
36. Zager RA, Shah VO, Shah HV et al. The mevalonate pathway during acute tubular injury: selected determinants and consequences. Am J Pathol 2002; 161: 681-692.
37. Zager RA, Johnson AC, Hanson SY. Sepsis syndrome stimulates proximal tubule cholesterol synthesis and suppresses the SR-B1 cholesterol transporter. Kidney Int 2003; 63: 123-133.
38. Zager RA, Johnson AC, Hanson SY. Renal tubular triglyercide accumulation following endotoxic, toxic, and ischemic injury. Kidney Int 2005; 67: 111-121.
39. Klingebiel T, von Gise H, Bohle A. Morphometric studies on acute renal failure in humans during the oligoanuric and polyuric phases. Clin Nephrol 1983; 20: 1-10.
40. Vollmar B, Glasz J, Leiderer R et al. Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction in warm ischemia-reperfusion. Am J Pathol 1994; 145: 1421-1431.
41. Basile DP, Fredrich K, Weihrauch D et al. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 2004; 286: F893-F902.
42. Sutton TA, Kelly KJ, Mang HE et al. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005; 288: F91-F97.
43. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62: 1539-1549.
44. Goto T, Fujigaki Y, Sun DF et al. Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats. Virchows Arch 2004; 444: 362-374.
45. Thurston G, Rudge JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463.
46. Naidu BV, Woolley SM, Farivar AS et al. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 2003; 126: 482-189.
47. Sutton TA, Mang HE, Campos SB et al. Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol 2003; 285: F191-F198.
48. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351: 159-169.
49. Chiao H, Kohda Y, McLeroy P et al. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997; 99: 1165-1172.
50. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199-2210.
51. Singer M, De Santis V, Vitale D et al. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364: 545-548.
52. Mital S, Zhang X, Zhao G et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 2000; 279: H2649-H2657.
53. Mital S, Magneson A, Loke KE et al. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol 2000; 36: 248-254.
54. Yamakuchi M, Greer JJ, Cameron SJ et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 2005; 96: 1185-1192.
55. Knotek M, Rogachev B, Wang W et al. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001; 59: 2243-2249.
56. Cunningham PN, Dyanov HM, Park P et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002; 168: 5817-5823.
57. Remick DG, Newcomb DE, Bolgos GL et al. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs cecal ligation and puncture. Shock 2000; 13: 110-116.
58. Echtenacher B, Weigl K, Lehn N et al. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 2001; 69: 3550-3555.
59. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-αin patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
60. Yuen PS, Dunn SR, Miyaji T et al. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004; 286: F1116-F1119.
61. Ramesh G, Reeves WB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-842.
62. Choi WI, Quinn DA, Park KM et al. Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med 2003; 167: 1627-1632.
63. Carattino MD, Cueva F, Zuccollo A et al. Renal ischemia-induced increase in vascular permeability is limited by hypothermia. Immunopharmacology 1999; 43: 241-248.
64. Green TP, Johnson DE, Marchessault RP et al. Transvascular flux and tissue accrual of Evans blue: effects of endotoxin and histamine. J Lab Clin Med 1988; 111: 173-183.
65. Ezaki T, Baluk P, Thurston G et al. Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. Am J Pathol 2001; 158: 2043-2055.
66. Manotham K, Tanaka T, Matsumoto M et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15: 1277-1288.
67. Matsumoto M, Tanaka T, Yamamoto T et al. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J Am Soc Nephrol 2004; 15: 1574-1581.